While There Are Still Unknowns, Monoclonal Antibodies Can Help in the Fight Against COVID-19
Antibodies have the Potential to Effectively Target Several Stages of the Disease with Evident Benefits at a Patient Level and a Systemic Level, According to a New White Paper by Trinity Life Sciences
WALTHAM, Mass.–(BUSINESS WIRE)–#covid—Trinity Life Sciences, a leader in global life sciences commercialization solutions, is sharing findings from its latest white paper entitled “Beyond Vaccines – How Monoclonal Antibodies Can Help in the Fight Against the COVID-19 Pandemic.” The paper finds that while there are still unknowns about monoclonal antibodies, such as real-life efficacy and long-term effects, they have the potential to effectively target several stages of the COVID-19 disease with evident benefits at a patient level (by alleviating symptoms and preventing progression to severe disease) and at a systemic level (by reducing the strain on the world’s overburdened health systems).
The white paper finds that if their role is proven in time, there will be a high demand for monoclonal antibodies, and there is a clear opportunity for pharma companies to develop new antibodies.
“While slow in their uptake, the US distribution of monoclonal antibodies for COVID-19 has started and several companies are developing new antibodies,” said Alexander Fink, Managing Partner, Europe, Trinity Life Sciences. “Vaccines are still the focus; however, it is increasingly clear that vaccines alone are not enough. All in all, there is a place for antibodies in the fight against COVID-19.”
About Trinity Life Sciences
Trinity Life Sciences is a trusted strategic commercialization partner, providing evidence-based solutions for the life sciences. With 25 years of experience, Trinity is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit trinitylifesciences.com.
Contacts
Elizabeth Marshall
Trinity Life Sciences
781-577-6376
[email protected]
